Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04833114 |
| Title | Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) (Pola-R-ICE) |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | GWT-TUD GmbH |
| Indications | |
| Therapies |
Carboplatin + Etoposide + Ifosfamide + Rituximab Carboplatin + Etoposide + Ifosfamide + Polatuzumab vedotin-piiq + Rituximab |
| Age Groups: | senior | adult |
| Covered Countries | ESP | DEU | AUT |